Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetix in COVID-19
NCT04851821Phase 1Completed
- Sponsor
- Hôpital Universitaire Sahloul
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quercetin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hôpital Universitaire Sahloul. Primary endpoint: Number of patients at 10 days. Started Jan 2021; status: completed.
02
Drugs
quercetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04851821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851821.